Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients

Cystic Fibrosis Clinical Trial

Official title:

Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02598999
• Other study ID #: ALX-009-CL-038
• Secondary ID: 2014-002401-38
• Status: Terminated
• Phase: Phase 1
• Start date: November 2015
• Est. completion date: December 2021

Study information

• Verified date: January 2022
• Source: Alaxia SAS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of a single ascending doses (SAD) and multiple ascending doses (MAD) of Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination (ALX-009) in healthy male volunteers and patients suffering from cystic fibrosis (CF) and non-CF bronchiectasis (NCFBE).

Description:

Part I: SAD of OSCN- and bLF in healthy male volunteers (cohorts 1 to 3) - Part II: SAD and MAD of ALX-009 in healthy male volunteers (cohorts 4 and 5) - Part III: MAD of OSCN- and bLF in patients suffering from cystic fibrosis (cohort III-1) and in healthy volunteers (cohorts III-2 and III-3) - Part IV: MAD of ALX-009 in healthy volunteers (Part IVa - Cohorts IV-1a to IV-3a) and in patients (Part IVb - Cohorts IV-1b to IV-3b)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 92
• Est. completion date: December 2021
• Est. primary completion date: December 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy male subject or
• Patient suffering from cystic fibrosis defined as a positive sweat chloride test or CF-causing mutations, documented in the patient's medical record or patient suffering from non-CF and non COPD bronchiectasis with a diagnosis confirmed by a chest CT scan demonstrating bronchiectasis in 1 or more lobes documented in the patient's medical record
• Aged between 18 and 50 years inclusive
• Subject's Body Mass Index between 18 and 30 kg/m²
• Subject with normal blood pressure, heart rate, ECG recording and laboratory parameters at the screening visit
• Subject having given a written informed consent prior to selection
• Subject covered by Health Insurance System and/ or in compliance with the recommendations of National Law in force relating to biomedical research

Specific Inclusion Criteria for patients:

• FEV1 more than or equal to 60% of predicted normal value
• Subject in a stable state (no exacerbation for 1 month or prescription of antibiotic by intravenous route)
• Females of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration / Female of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal

Exclusion Criteria:

• Presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic or infectious disease
• Frequent headaches and/or migraines, recurrent nausea and/or vomiting
• Symptomatic hypotension
• Blood donation (including in the frame of a clinical trial) within 2 months before administration
• General anaesthesia within 3 months before administration
• Presence or history of drug hypersensitivity, or any allergic disease
• Medical history of reactions to cow's milk proteins
• Subject who can not be contacted in case of emergency
• History or presence of drug or alcohol abuse
• Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests
• Subject who, in the judgement of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.

Specific exclusion criteria for study Parts III and IV:

• Known bronchial hyper-reactivity to drug inhalation
• Known contra-indication to inhaled salbutamol
• Subject with bronchial hyper-reactivity, defined by a positive response to bronchodilator with FEV1 increase = 200 mL

Specific exclusion crtieria for patients:

• Active allergic bronchopulmonary aspergillosis currently treated
• Medical history of allergic bronchopulmonary aspergillosis in the past 2 years.

Related Conditions & MeSH terms

• Bronchiectasis
• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• ALX-009
Solution for inhalation administered through nebulization
• OSCN-
Solution for inhalation administered through nebulization
• bLF
Solution for inhalation administered through nebulization
• Placebo
Solution for inhalation administered through nebulization, Sodium Chloride 0.9%

Locations

Country	Name	City	State
France	Eurofins Optimed	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
Alaxia SAS

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	For patients only, characterization of sputum microbiota using genomic technologies		D14 post dosing
Primary	Safety and tolerability: number of subjects who experience serious adverse events, adverse events, potential clinically significant changes in ECG, 24-holter, vital signs, physical examinations, laboratory tests, spirometry, O2 saturation (Part III only)		Day (D) 8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Maximal concentration (Cmax) of bLF and SCN- in plasma, sputum and urine (for SCN- only)		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Area under the curve (AUC) of bLF and SCN- in plasma, sputum and urine (for SCN- only)		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	First time to reach Cmax (Tmax) of bLF and SCN- in plasma, sputum and urine (for SCN- only)		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration half life of bLF and SCN- in plasma, sputum and urine (for SCN- only)		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of anti-bLF antibodies in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of IL-1ß in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of IL-6 in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of IL-8 in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of IL-10 in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of TNF-a in blood and sputum		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of SC5b-9 in blood		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	Concentration of total IgE in blood		D8 post dosing for part I and D14 post dosing for parts II, III and IV
Secondary	For patients only, quantitative assessment of different species in sputum	Staphylococcus aureus, Staphylococcus aureus MRSA, Pseudomonas aeruginosa, Pseudomonas aeruginosa MDR, Haemophilus influenzae, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Burkholderia cepacia complex, Aspergillus fumigatus and Aspergillus terreus	D7 post dosing
Secondary	For patients only, volume of sputum over 24hours period		D8 post dosing